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AModel for Communication About
Longshot Treatments in the Context
of Early Access to Unapproved,
Investigational Drugs
Eline M. Bunnik, Erasmus University Medical Center
Nikkie Aarts, Erasmus University Medical Center
When seriously ill patients run out of standard treatment
options, they may consider nonstandard treatment
options such as expanded access, also known as
“compassionate use.” Through expanded access pro-
grams, patients are given access to investigational drugs
that are still under development and not yet approved for
marketing. As the safety and efficacy of unapproved
drugs have not been fully established, it is uncertain
whether these drugs will offer medical benefit. Especially
when the compound is in an early stage of the drug
development process, its odds of success may be low or
“longshot.” Expanded access raises ethical concerns, nota-
bly that seriously ill patients may overestimate the bene-
fits of an investigational drug and underestimate its
safety issues, fail to make informed decisions, and
become susceptible to false hope and exploitation (Dar-
row et al. 2015). The communication model proposed by
Weiss and Fiester (2018) and its central distinction
between low-odds and no-odds treatment can be used to
assist seriously ill patients and their treating physicians
not only with decision making with regard to initiating
expanded access to investigational therapies but also with
monitoring and managing their effects. Thus, it may help
to overcome some of the ethical problems associated with
expanded access.
Systems for expanded access differ across countries,
but have a set of conditions in common: Patients must be
suffering from serious or life-threatening diseases must
have exhausted standard treatment options, and must not
be eligible for participation in clinical trials (Jarow et al.
2017). The managing physician must believe that the
potential benefits of the drug will outweigh the risks. A
regulatory authority such as the Food and Drug Adminis-
tration (FDA) will need to approve the request (FDA 2017).
In some countries, including the United States, requests
must also be evaluated by an institutional review board.
Importantly, the pharmaceutical company must be willing
to supply the drug, often at no cost. Finally, patients must
provide informed consent.
Requests for individual patients are usually initiated in
“back against the wall” situations by treating physicians
who believe that a last-ditch intervention might save or
benefit their patient. Expanded access has a therapeutic
aim, not a research aim. The odds that the drug will benefit
the patient, however, may vary depending on the physical
condition of the patient, on the drug itself and its stage of
development—and consequently on the level of available
evidence. Early in the drug development trajectory, for
instance, the odds of success are slim. Among patients
enrolled in oncology Phase I clinical trials, average
response rates are around 5% (Kimmelman 2016).
Response rates are probably lower in patients who fail to
meet the inclusion criteria of trials because of poor physi-
cal condition. Enrolling patients in Phase I trials can be
thought of as very-low-odds to no-odds and is therefore
considered nontherapeutic.
On the other end of the spectrum are drugs that have
successfully completed Phase III clinical trials. It usually
takes up to a year for the regulatory authorities to evaluate
the dossier and decide on marketing authorization (Down-
ing et al. 2012), and, in many countries, another couple of
months or years before health technology assessment bod-
ies make reimbursement decisions and the drug in effect
becomes available to patients (Bergmann et al. 2016). In the
meantime, patients may seek access to the drug through
expanded access programs. Pending marketing approval,
a drug is not (yet) standard of care, but high-level evidence
on the drug’s safety and efficacy is available. Thus,
expanded access to post-Phase III unapproved drugs is not
an example of longshot therapy. Doctors and patients can
make evidence-based decisions on whether or not to initi-
ate the unapproved therapy.
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In contrast, Phase II unapproved drugs can be thought
of as a form of longshot therapy. Weiss and Fiester (2018)
distinguish longshot care “where there is a low likelihood
of success” from fantasy care “where there is no chance of
success” (4). A meta-analysis of more than 500 Phase II
cancer trials showed a median response rate of 30% for
personalized or targeted therapies (Schwaederle et al.
2015). Although notoriously few newly approved drugs
are in effect lifesaving or fully curative, patients seeking
expanded access may instead be aiming for prolongation
or quality of life. While Phase II investigational drugs may
have a low likelihood of success at providing these bene-
fits, this likelihood is not zero. Just like in referral pediatric
care, the physician proposes something that he or she
knows is “unlikely to work [but] conceivably could work
(and sometimes does)” (Weiss and Fiester 2018, 3).
Expanded access to early-phase investigational drugs may
thus be considered a form of longshot or low-odds ther-
apy, but not fantasy therapy.
Expanded access is usually only pursued after the drug
has completed Phase II a/b clinical trials, that is, after either
basic safety and efficacy studies have been conducted in
patients with the relevant indications. After all, the doctor
should have considered the available evidence and estab-
lished a favorable balance of risks and potential benefits,
before deciding to request expanded access for the patient.
This balance may be both acceptable and low-odds. When
patients are seriously or terminally ill and have run out of
standard treatment options, it is not unreasonable for them
to pursue a longshot therapeutic option.
As described byWeiss and Fiester for quaternary pediat-
ric care, however, the use of investigational drugsmay grad-
ually turn into fantasy therapy. As physicians usually resort
to expanded access only when all other options have failed,
most patients are very sick. Investigational drugs, like all
other drugs, may have side effects or lead to serious adverse
drug reactions, and thus harm patients rather than help
them. Also, there may be psychological and social opportu-
nity costs associated with “fighting” and not accepting that
death will be likely. In order to avoid these harms and mini-
mize suffering, the physician may at some point wish to dis-
continue the investigational treatment. When doctors and
patients are deciding whether or not to pursue expanded
access, they should discuss this scenario. The communica-
tion model proposed byWeiss and Fiester can be of help.
Despite important differences, in particular that adult
patients are capable of providing informed consent and
that decision making takes place within the doctor–patient
relationship rather than among a hospital-based team of
professionals and parents, the four stages described by
Weiss and Fiester through which last-ditch pediatric inter-
ventions go awry can be translated to the context of
expanded access. In the first stage, the physician and
patient decide—together—to initiate a request for
expanded access. In the second stage, the investigational
treatment commences. In the third stage, the patient does
not respond to the treatment as hoped, and the physi-
cian—and possibly the patient as well—begins to
understand that the odds of success are “moving toward
zero.” In the fourth and final stage, the treatment has
clearly “reached the fantasy stage” and should be stopped.
In the first stage, as part of the informed consent process,
physicians should not only inform patients about the low
odds of success in general terms, but also paint a picture of
what will happen “in the likely event that the treatment
fails” (Weiss and Fiester 2018, 3). What may occur in Stage
3? What would success of the investigational treatment
look like, and what would failure look like? When will the
line between Stage 3 and Stage 4 be crossed, and what will
discontinuation of the treatment look like? Ideally, the
physician and the patient should agree beforehand upon
benchmarks for success and failure, and how these would
shift the care plan.
Before patients and their treating physicians venture
into expanded access, they should go through an informed
consent process that explicitly addresses likely scenarios of
failure and involves agreement between doctors and
patients upon benchmarks for continuation or discontinua-
tion of the investigational drug. This would help to elicit a
realistic understanding by the patient of the (small) likeli-
hood of success of expanded access, reduce therapeutic
misconceptions, and prevent false hope and unnecessary
harm. Drawing lines between low-odds and no-odds ther-
apeutic interventions will always be both difficult and
arguable, especially for early-phase drugs. Nevertheless,
the informed consent process for expanded access to inves-
tigational drugs will improve through a discussion of these
lines and an agreement between patients and their treating
physicians upon a course of action in the [likely] event of
failure, prior to the start of the investigational treatment.
As the—often criticized—Right-to-Try movement in
the United States is raising awareness of expanded access
and seeking to increase its accessibility (Holbein et al.
2015), demand among patients for unapproved drugs
around the world is expected to rise. Adequate informed
consent processes that explicitly rebut unwarranted thera-
peutic optimism will be crucial for morally responsible
practices of expanded access in the future.
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Reframing Fantasy: Toward a Common
Language of Hope, Dying, and Death in
Long-Shot Pediatrics
Courtney Addison ,Monash University
Courtney Hempton,Monash University
This response piece engages the target article’s suggestion
for a communication rubric around long-shot pediatric
medicine (Weiss and Fiester 2018). We offer constructive
criticism of the authors’ proposal of “fantasy” as a framing
of the inappropriate expectations parents may have of
their child’s care. We suggest that harm reduction could be
facilitated by more nuanced understandings of both medi-
cal and parental roles, as well as of the broader cultural
contexts of biomedicine.
Clear and unambiguous communication between clini-
cal care teams and families of the sickest children is ethi-
cally essential, particularly when navigating low-odds,
“longshot” curative treatment. For children with severe or
unusually complex health problems, practitioners will
often undertake medical action that offers an improbable
but possible chance of recuperation. In “From ‘Longshot’
to ‘Fantasy,’” Weiss and Fiester propose a four-stage rubric
for medical practitioners who must communicate to a
patient’s family that their child’s curative odds have
slipped from low to zero. Through two affecting case stud-
ies, we see how such treatment can slide from improbable
to impossible, often with great rapidity. The authors
respond to this by delineating a pathway from “longshot
hope” (Stage 1), through “initial actions” (Stage 2), to
“threshold” (Stage 3), and “fantasy” (Stage 4); the
transition between Stages 3 and 4 presents a particular
challenge for practitioners. While the authors’ intent to
minimize potential harms through a formalized communi-
cation rubric is worthwhile, we reject the prescription of
nonmedical “fantasy” terminology.
We identify a degree of semantic slippage in the
authors’ use of the term “fantasy.” They employ “fantasy”
to describe a medical reality (“fantasy care where there is
no chance of success,” 4), but also propose that it be
used as a communicative device (“a colloquial, nonmedical
concept that carries a precise meaning to lay individuals,”
8). Specifically, they attempt to position the term as a
replacement for both “the highly criticized ‘futility’ and the
newer concept of ‘potentially inappropriate treatment’” (3).
They note, as well, that “fantasy” differs from these terms
“both theoretically . . . and practically in use with families of
very sick children” (3). It is primarily the term’s communi-
cative application that we take issue with.
The term “fantasy” as proposed is based on a limited
rendering of the family, which reproduces a divide
between “rational” experts and “irrational” laypeople. The
authors claim that “fantasy” offers families “a lay termi-
nology that conveys a very precise meaning, namely, that
the goal of cure is now only ‘wishful thinking,’
‘unrealistic,’ and ‘make believe’” (22); no evidence is
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